Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate

Head and Neck

Volumn 27, Issue 12, 2005, Pages 1022-1027

  Lin, Ching Hung ^a   Yen, Ron Fan ^a   Jeng, Yung Ming ^a   Tzen, Chin Yuan ^b   Hsu, Chiun ^a   Hong, Ruey Long ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adenoid cystic carcinoma; Imatinib mesylate; KIT; PDGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DNA; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADULT; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; EDEMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG METASTASIS; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PLEURA EFFUSION; PLEURA METASTASIS; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR VOLUME; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PLEURAL EFFUSION, MALIGNANT; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 28244448498     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20274     Document Type: Article

References (25)

1. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 1974;128:512-520.
2. de Haan LD, De Mulder PH, Vermorken JB, et al. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992;14:273-277.
3. Hill ME, Constenla DO, A'Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997;33:275-278.
4. Vermorken JB, Verweij J, De Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993;4:785-788.
5. Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996;7:867-869.
6. Airoldi M, Bumma C, Bertetto O, et al. Vinorelbine treatment of recurrent salivary gland carcinomas. Bull Cancer 1998;85:892-894.
7. Perrot E, Davy N, Poubeau P, Arvin-Berod C. Chemotherapy with paclitaxel for lung metastases of cystic adenoid carcinoma. A case report and review of the literature. Rev Pneumol Clin 2003;59:371-374.
8. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956-960.
9. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 2002;15:687-691.
10. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:586-593.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
12. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
13. Dori S, Vered M, David R, Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 2002;31:463-467.
14. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002;24:632-636.
15. Gibbons MD, Manne U, Carroll WR, et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 2001;111:1373-1378.
16. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004;26:829-831.
17. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005;23:585-590.
18. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
20. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003;63:513-522.
21. Shaul Y. c-Abl: activation and nuclear targets. Cell Death Differ 2000;7:10-16.
22. Torihashi S, Nishi K, Tokutomi Y, et al. Blockade of kit signaling induces transdifferentiation of interstitial cells of Cajal to a smooth muscle phenotype. Gastroenterology 1999;117:140-148.
23. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004;10:3282-3290.
24. Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103:538-544.
25. Taieb J, Maruyama K, Borg C, et al. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 2004;103:1966-1967.